ArticleFunctional & integrative genomics2025
Integrated multi-omics analysis of UL16-binding protein 2 as a prognostic and immunotherapy biomarker for colorectal cancer.
Article in Functional & integrative genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative genomic and functional analysis of RAB3B in lung adenocarcinoma: associations with m6A modification and ceRNA networks.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUL16-binding protein 2 (ULBP2) is an important immune regulatory molecule involved in natural killer cell activation and tumor immune surveillance, although the specific role and clinical significance in colorectal cancer (CRC) require further exploration.
methodsULBP2 expression in CRC vs. normal tissues was analyzed using The Cancer Genome Atlas and the Gene Expression Omnibus databases, along with potential associations with clinicopathological features, while the diagnostic value was assessed with receiver operating characteristic (ROC) curves and the prognostic impact by Kaplan-Meier and Cox regression analyses. Additionally, the regulatory mechanisms of ULBP2 were explored by investigations of promoter DNA methylation, m6A regulation, and immune cell infiltration. Finally, cellular experiments were conducted to evaluate ULBP2 as a potential biomarker to predict CRC progression.
resultsULBP2 upregulation was significantly correlated with an advanced pathological stage of CRC. ROC curve analysis indicated that ULBP2 has strong diagnostic value. Kaplan-Meier survival analysis showed that high ULBP2 expression was predictive of a poorer prognosis. Cox regression analysis highlighted ULBP2 as an independent prognostic factor. ULBP2 expression was linked to promoter methylation, m6A regulation, and immune cell infiltration. Cellular experiments showed that ULBP2 knockdown suppressed CRC progression.
conclusionULBP2 has potential as a prognostic biomarker and therapeutic target of CRC. These findings provide valuable insights for future studies of tumorigenic mechanisms and clinical applications.
Indexed as
Identifiers
40545483What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.